Celldex Therapeutics, Inc. (CLDX)
NASDAQ: CLDX · Real-Time Price · USD
32.14
-1.09 (-3.28%)
At close: Apr 29, 2026, 4:00 PM EDT
31.52
-0.62 (-1.93%)
After-hours: Apr 29, 2026, 5:32 PM EDT
Celldex Therapeutics Employees
Celldex Therapeutics had 198 employees as of December 31, 2025. The number of employees increased by 12 or 6.45% compared to the previous year.
Employees
198
Change (1Y)
12
Growth (1Y)
6.45%
Revenue / Employee
$7,803
Profits / Employee
-$1,306,854
Market Cap
2.52B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 198 | 12 | 6.45% | 198 | 0 |
| Dec 31, 2024 | 186 | 26 | 16.25% | 186 | 0 |
| Dec 31, 2023 | 160 | 12 | 8.11% | 160 | 0 |
| Dec 31, 2022 | 148 | 14 | 10.45% | 148 | 0 |
| Dec 31, 2021 | 134 | 9 | 7.20% | 132 | 2 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Zai Lab | 1,784 |
| Ultragenyx Pharmaceutical | 1,371 |
| ADMA Biologics | 647 |
| Tarsus Pharmaceuticals | 370 |
| Vera Therapeutics | 249 |
| Relay Therapeutics | 192 |
| Soleno Therapeutics | 182 |
| Immunome | 177 |
CLDX News
- 15 days ago - Celldex Therapeutics Transcript: H.C. Wainwright 4th Annual Inflammatory Skin Disease Virtual Conference - Transcripts
- 16 days ago - Celldex to Present at Upcoming Investor Conference - GlobeNewsWire
- 23 days ago - Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares - GlobeNewsWire
- 27 days ago - Celldex Announces Pricing of $300 Million Public Offering of Common Stock - GlobeNewsWire
- 4 weeks ago - Celldex Announces Proposed Public Offering of Common Stock - GlobeNewsWire
- 4 weeks ago - Celldex Presents Positive Data from Phase 2 Chronic Spontaneous Urticaria and Phase 2 Cold Urticaria and Symptomatic Dermographism Studies Demonstrating Rapid, Profound and Durable Improvements in Patient Quality of Life at AAD 2026 - GlobeNewsWire
- 7 weeks ago - Celldex Therapeutics Transcript: Leerink Global Healthcare Conference 2026 - Transcripts
- 2 months ago - Celldex Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference - Transcripts